Arizona · Nonprofit
INTERNATIONAL CANCER ADVOCACY NETWORK
INTERNATIONAL CANCER ADVOCACY NETWORK (Arizona) receives grants from 29 organizations whose IRS filings report $1,557,839 to it, the largest being BERNARD A EGAN FOUNDATION INC ($450,000). 16 of them have funded it in more than one year.
- Revenue FY2024
- $2.7M
- Funders on record
- 29
- Grants received
- $1.6M
- Net assets
- $5.3M
What International Cancer Advocacy Network does
Mission
Ican's mission is two-fold: to optimize stage iv cancer patient survival and work to attain the highest possible quality of life. Ican assists stage iv cancer patients with 1) direct patient navigation and customized advocacy services; 2) referrals to oncologists in academic medical centers as well as community practices; 3) educating patients regarding the imperative of molecular profiling; 4) expediting access to molecular profiling; 5) educating patients and their care partners regarding clinical trials and molecular matching of the patient to clinical trials; and 6) expediting patient access to compassionate use/expanded access programs. Ican is a pan-heme cancer, pan-solid tumor, pan-sarcoma, and pan-rare cancer patient advocacy organization and research advocacy organization. Ican also focuses on expanding patient access and galvanizing our collaborators to assist under-resourced patient communities in the us and abroad with customized information services. Ican annually awards r
As stated on its FY2024 Form 990.
Programs
Patient navigation programs, including patient program services/research advocacy programs/cancer research services of which 300,000 was awarded in grants to investigators associated with or collaborating with ican's international research consortium, including the university of texas md anderson cancer center, the university of texas southwestern, the university of pennsylvania, the university of pittsburgh, and the university of california, san francisco. Grants were awarded for proposals relating to molecular alterations and resistance mechanisms, development of drugs with new mechanisms of action, development of early detection assays, and research regarding leptomeningeal disease (lmd). The 2023-2024 grant cycle was funded by ican's special events, including the annual fistbump fundraiser and the annual applied underwriting golf tournament as well as by ican memorial and tribute programs. Ican's exon 20 international research consortium consists of top thoracic research oncologists and scientists who have produced an array of transformative journal articles that are propelling the field of actionable mutations forward. Ican's patient services focus on hematological, solid…
$535,000 spentof which $300,000 as grants56% of program spendingPatient, care partner, and clinician education/ u.s. And global patient access programs-focusing on patient access to molecular testing and precision medicine; u.s. And global access issues related to under- resourced patient communities; early detection (imaging and molecular diagnostics); ongoing health information projects for exon 20 group, met crusaders, biomarker collaborative, and pan-tumor ican programs; and access issues regarding expanded access/pre-approval access/compassionate use programs in the u.s. And abroad. Ican's public policy advocacy efforts were vigorously pursued at the state and federal levels, including issues such as the inflation reduction act and fixing the small molecule penalty; weighing in on prescription drug affordability boards; supporting pbm reform; supporting 340b program reform; advocating the preservation of the bayh-dole program; supporting biomarker testing bills (passed in 20 states and counting); supporting co- pay accumulator and rebate reform bills (active participant in the "all copays count coalition"), and opposing state-led efforts that impede patient access to novel therapeutics, such as step therapy/fail-first therapy where we…
$214,650 spent22% of program spendingMolecular profiling connection services/clinical trials matching services: 1) advising patients on the importance of next-generation sequencing and educating them about the array of molecular profiling technologies that can either be accessed by patients and/or researchers--dna, rna, and thus multi-omics: genomics, proteomics, transcriptomics, metabolomics, methylation, immune cell studies, and so forth; 2) reviewing molecular profiling reports with patients and their care partners; 3) convening ad hoc molecular tumor boards where needed, with the input of members of ican's biomarkers council, physicians council, and drug development council; 4) educating patients about molecular tumor boards (e.g. Target cancer's track study, asco tapur study; roche navify); and, 5) connecting patients to principal investigators and study teams on a pan-tumor/pan- heme/pan-rare cancer basis if an appropriate clinical trial is a molecular match. Ican and its support groups are also engaged in the areas of decentralizing trials; "just-in-time" trials; and expediting the transfer of patients from one clinical trials site (mid-regimen) to another more convenient site (u.s. To u.s. Or eu to u.s.).…
$207,979 spent22% of program spending
The 3 programs described on its FY2023 Form 990, listed largest first by expense. Program spending in total: $957,629.
The organization over time
Each line starts at 100 in 2020, so what you read is the shape rather than the size: 150 means half as much again as 2020, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $3.8M to $5.3M (+39%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
99% of INTERNATIONAL CANCER ADVOCACY NETWORK’s revenue is contributions — more reliant on donations than three-quarters of its peers (82% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 0 of the last 5 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Who funds it, year by year
2017 → 2023: the base broadened from 3 funders to 16 funders, grant income rose $21k → $386k.
13 of 29 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 39% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of INTERNATIONAL CANCER ADVOCACY NETWORK’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
INTERNATIONAL CANCER ADVOCACY NETWORK has a broad base — no single funder exceeds 29% of grant income, and it takes 4 funders to reach half.
the vertical line marks half of all grant income — 4 funders to its left
48% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund INTERNATIONAL CANCER ADVOCACY NETWORK.
Largest funder’s share by year: 2017 47% · 2018 29% · 2019 73% · 2020 51% · 2021 33% · 2022 55% · 2023 26% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
42% of INTERNATIONAL CANCER ADVOCACY NETWORK's funders are still giving 3 years after their first grant; 55% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
INTERNATIONAL CANCER ADVOCACY NETWORK draws 100% of its grant income from funders outside Arizona, across 10 states in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $601k arriving through sponsors registered in 11 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
INTERNATIONAL CANCER ADVOCACY NETWORK runs a healthier operating margin than three-quarters of the 2,910 philanthropy nonprofits its size.
this organization peer median middle 50% of peers· 2,910 philanthropy nonprofits $1M–$10M, FY2024
Organizations like INTERNATIONAL CANCER ADVOCACY NETWORK
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Arizona
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
92% of spending goes to programs.
Governance
Public support
98%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Part of a family of 2 related entities
- Biomarker Collaborative Inc · exempt
- Met Crusaders Inc · exempt
Screen this organization
A dated, signed PDF of the compliance screen for INTERNATIONAL CANCER ADVOCACY NETWORK: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds INTERNATIONAL CANCER ADVOCACY NETWORK?
- INTERNATIONAL CANCER ADVOCACY NETWORK (Arizona) receives grants from 29 organizations whose IRS filings report $1,557,839 to it, the largest being BERNARD A EGAN FOUNDATION INC ($450,000). 16 of them have funded it in more than one year.
- How many funders does INTERNATIONAL CANCER ADVOCACY NETWORK have?
- IRS filings report 29 organizations giving $1,557,839 in grants to INTERNATIONAL CANCER ADVOCACY NETWORK, 16 of which have funded it in more than one year.
- Who is the largest funder of INTERNATIONAL CANCER ADVOCACY NETWORK?
- BERNARD A EGAN FOUNDATION INC is the largest funder on record, with $450,000 in grants. The full list of funders is on this page.
- How can an organization like INTERNATIONAL CANCER ADVOCACY NETWORK find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Arizona. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2020–2024), and the filings of 29 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing